Recent studies have shown that low-dose apatinib (VEGFR2-TKI) significantly improves the therapeutic effect of PD-1/PD-L1 inhibitors by modulating the tumor microenvironment, delaying tumor growth, reducing the number of metastases and prolonging survival in mouse models (93). Here, CD274 is linked to neoplasm.